DOVETAIL vamikibart – approximately a quarter of patients exhibit a ≥15 letter gain with anti-IL-6 monotherapy 80 Sharma, et al. A Novel Intravitreal Anti-IL-6 Monoclonal Antibody for Uveitic Macular Edema (UME): Preliminary Results From the Phase 1 DOVETAIL Study. Presented at the American Society of Retina Specialists, Seattle, WA, July 28 – August 1, 2023 DOVETAIL vamikibart ≥15 letter gainers at Week 12